Skip to main content
Fig. 3 | BMC Ophthalmology

Fig. 3

From: Correlation between improvement in visual acuity and QOL after Ranibizumab treatment for age-related macular degeneration patients: QUATRO study

Fig. 3

a The mean changes in best corrected visual acuity (BCVA) from baseline. Mean change in logMAR BCVA from baseline was − 0.13 at 3 months and − 0.14 after 1 year of treatment (*p < 0.0001). b The mean changes in central macular thickness (CMT). Changes in the CMT were examined by OCT for each patient. Mean change in CMT from baseline was − 76.08 μm at 3 months and −63.41 μm at 12 months (*p < 0.0001). (c) Mean changes in the NEI-VFQ-25 composite score for one year. Mean change in the NEI-VFQ-25 composite score from baseline was + 4.5 at 3 months, and + 6.3 at 12 months (*p < 0.0001)

Back to article page
\